Skip to content

Study on infusion rate of snake antivenom therapy

Study on infusion rate of snake antivenom therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2007/005
Enrollment
206
Registered
2007-05-18
Start date
2007-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Snakebites requiring antivenom administration

Interventions

Patients will be randomly allocated to two groups and one will receive antivenom dose over 20 minutes while the others will receive the same dose over 2 hours.

Sponsors

IRQUE Project
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a possible clinical diagnosis of a snakebite

Exclusion criteria

Exclusion criteria: * Under 14 years of age * Pregnant ladies * Previous administration of antivenom * Refusal of consent

Design outcomes

Primary

MeasureTime frame
Proportion with severe systemic allergic reactions within 4 hours of commencement of antivenom [within 4 hours of commencement]

Secondary

MeasureTime frame
* Proportion with elevated mast cell tryptase * Proportion with elevated antivenom specific IgE * Hospital length of stay * Proportion with mild allergic reactions * Proportion with delayed administration of -further antivenom therapy * Proportion developing serum sickness []

Countries

Sri Lanka

Contacts

Public ContactDr. Ariaranee Gnanathasan

Senior Lecturer

ariaranee2000@yahoo.com4(0)112689188

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026